Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients

Hemoglobin

Volumn 35, Issue 1, 2011, Pages 13-21

  Al Nood, Hafiz A ^a   Al Khawlani, Mona M ^a   Al Akwa, Ahmed ^a  

^a SANA A UNIVERSITY   (Yemen)

Author keywords

Fetal hemoglobin (Hb F); Hydroxyurea (HU); Sickle cell disease; Yemen

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN A2; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CATION EXCHANGE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EVALUATION AND FOLLOW UP; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PRESCHOOL CHILD; RETICULOCYTE; RETICULOCYTE COUNT; SCHOOL CHILD; SICKLE CELL ANEMIA; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; YEMEN;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BIOMARKERS, PHARMACOLOGICAL; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; FETAL HEMOGLOBIN; HEMATOLOGIC TESTS; HEMOGLOBIN A; HUMANS; HYDROXYUREA; MALE; YEMEN; YOUNG ADULT;

EID: 79952180751     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.551748     Document Type: Article

References (20)

1. 2 on the polymerization of Hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci USA. 1993;90(11):5039-5043.
2. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease rates and risk factors. N Engl J Med. 1991;325(1):11-16.
3. Charache S, Terrin ML, Moore RD, et al. and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332 (2):1317-1322.
4. Ma Q, Wysznski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants to response to hydroxyurea. Pharmacogenomics J. 2007;7(6):386-394. (Pubitemid 350187450)
5. Al-Nood H, Al-Ismail S, King L, May A. Prevalence of the sickle cell gene in Yemen: a pilot study. Hemoglobin. 2004;28(4):305-315. (Pubitemid 39579264)
6. Al-Nood H. Thalassemia trait in outpatient clinics of Sana'a City, Yemen. Hemoglobin. 2009,33(3-4):242-246.
7. Ganid AA, Hummad NA, Tamim KA. Consanguineous marriage in the capital city Sana'a, Yemen. J Biosoc Sci. 2004;36(1):111-121. (Pubitemid 38095191)
8. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006;4(1):59.
9. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651. (Pubitemid 37430269)
10. Autl A. US FDA approves first drug for sickle cell anemia. Lancet. 1998;351(9105):809.
11. Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2005;105(2):545-547. (Pubitemid 40070734)
12. Al-Jam'a AH, Al-Dabbous IA. Hydroxyurea in sickle cell patients from Eastern Saudi Arabia. Saudi Med J. 2002;23(3):277-281.
13. Jayabose S, Tugat O, Sandoval C, et al. Clinical and hematological effect of hydroxyurea in children with sickle cell anemia. J Pediatr. 1996;129(4):559-565. (Pubitemid 27490793)
14. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol. 1998;20(1):26-31. (Pubitemid 28119752)
15. Schultz WH, Davis JS, Pickens CV, Mortier NA, Howared TA, Ware RE. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease, Blood. 2004;103(6):2039-2045. (Pubitemid 38326218)
16. Al-Saqladi A, Delpisheh A, Bin-Gadeem H, Brabin BJ. Clinical profile of sickle cell disease in Yemeni children. Ann Trop Paediatr. 2007;27(4):253-259. (Pubitemid 350167610)
17. El-Hazmi MA, Warsy AS. Molecular studies on Yemeni sickle cell disease patients: Xmn I polymorphism. East Mediterr Health J. 1999;5(6):1183-1187.
18. Al-Nood HA. Prevalence of sickle cell gene in Yemen. Ph.D. thesis, University of Wales, Swansea, Wales, UK. 2004;116-125.
19. Al-Saqladi AW, Brabin BJ, Bin-Gadeen HA, Kanhai WA, Phylipsen M, Harteveld CL. β-Globin cluster haplotypes in Yemeni children with sickle cell disease. Acta Haematol. 2010;123(3):182-185.
20. Al-Nood H. Thalassemia and G-6-PD deficiency in sickle cell patients in Taiz, Yemen. East Mediterr Health J. 2011;17(8) (in press).